# 1. Financial Performance ## A. Key Figures * **Consolidated Revenue:** **₹6,120 Cr** (Q2 FY26) (+17% YoY) * **Consumer Wellness Revenue:** **₹640 Cr** (+31% YoY) * EBITDA: ₹20.2 Cr (+38% YoY) · Margin: 32.9% (+500 bps YoY) * **Net Profit:** **₹1,260 Cr** (+38% YoY) * **H1 Operating Margin:** **~32%** * **Intangible Assets:** **₹2,600 Cr** (up from ₹1,300 Cr in 6 months) ## B. Revenue Growth * **Strong Core Momentum:** Double-digit organic revenue growth achieved despite lapping peak Revlimid sales, highlighting resilient underlying demand. * **Product Transition Impact:** Revlimid revenue has sharply declined post-Q1 and will remain negligible in near-term quarters, creating a headwind to US growth trajectory. * **US Business Stability:** Excluding Revlimid and Mirabegron, US base business remains stable with continued **single-digit price erosion**, offset by operational discipline. ## C. Profitability Trends * **Robust Margin Expansion:** EBITDA margin surged 500 bps YoY to 9%, driven by strong profitability in international and domestic segments, despite US headwinds. * **Sustained Profit Growth:** Net profit rose 38% YoY, aligned with EBITDA momentum, reflecting effective cost control and operating leverage. ## D. Margin Expansion * **Cost Optimization Underway:** Strategic cost reduction initiatives are being implemented to enhance margins and competitiveness without impacting full-year guidance. * **Product-Level Margin Dynamics:** Comfort Click contributes at a lower margin than group average but is not expected to affect overall margin targets. ## E. Balance Sheet Health * **Deleveraging Focus:** Proposed fundraising primarily aimed at reducing debt, with a strict **target net debt/EBITDA ratio of 1x**, allowing temporary tolerance up to **2x** for M&A. * **M&A-Driven Cost Pressures:** Other operating expenses rose ~32% due to recent integration of Amplitude and CCL, along with project-specific M&A costs. * **R&D Intensity Rising:** Intangible assets under development doubled in six months, signaling aggressive pipeline and innovation investment. --- # 2. Product & Therapy Performance ## A. Key Figures * **Chronic Portfolio Contribution:** **44.5%** (IQA MAT Sep '25) (+500 bps vs. 3 years ago) * Vaccine Impact: 3–5 million annual severe flu cases · 290,000–650,000 global respiratory deaths yearly ## B. Specialty Portfolio * **Myrbetriq Gaining Traction:** Product shows steady market share growth and strong commercial momentum in specialty urology. * **Revlimid Decline Continues:** Sales significantly lower in Q2 vs. Q1, consistent with prior trend. * **Semaglutide Launch Positioning:** Company expects to be in the **first wave of Semaglutide launch in India**, signaling early-mover advantage in GLP-1 space. ## C. Generics & 505(b)(2) * **Beizray Launch Accelerates 505(b)(2) Momentum:** First 505(b)(2) injectable launched in US; **polysorbate-free formulation** offers clinical advantages and strong initial uptake. * **US Generics Growth Engine:** Driven by diversified portfolio, **specialty focus**, and **pediatric rare disease** initiatives, with transdermals showing **sticky demand** and **strong share**. * **Injectables Scaling Up:** Despite past facility constraints, Zydus is building US injectables business with **Beizray** and partner launches; meaningful contribution expected in **2–3 years**. * **Near-Term Catalysts:** **Generic Copaxone** set for imminent US launch; **Sitagliptin 505(b)(2)** revenue plateauing ahead of genericization. * **International Approvals:** Secured **first NOC from Health Canada** for Varenicline, with **three NOCs total** to date, expanding regulatory footprint. ## D. Chronic & Rare Diseases * **Chronic Portfolio Expansion:** Now **5% of total business**, reflecting strategic shift and outperformance in **cardiology, gynecology, and oncology**. * **Saroglitazar Poised for PBC Entry:** Positioned as **third therapy in PBC market**, with **14–15 month launch window** and strong US commercial potential. * **PBC Market Validation:** Growing uptake and **$5B Gilead acquisition** underscore segment’s high unmet need and value. ## E. Vaccine Launches * **VaxiFlu Establishes Leadership:** **India’s first trivalent flu vaccine** aligned with WHO; strong domestic uptake and market share capture. * **Vaccine Strategy: Domestic-First, Global Next:** Current focus on **India (flu, rabies, MR)**; **global expansion via tenders expected by FY27–28**, supported by **TCV prequalification**. --- # 3. Geography & Market Mix ## A. Key Figures * **US Formulations Revenue:** **₹2,740 Cr** (+14% YoY) * **International Formulations Revenue:** **₹750 Cr** (+39% YoY) * **India Branded Formulations Growth:** **+9% YoY** ## B. US Market Trends * **Growth Despite Volatility:** US formulations posted strong double-digit growth on volume expansion and **seven new product launches**, though QoQ revenue dipped amid unaddressed audio issues. * **Stable Seasonality:** Comfort Click revenue is evenly distributed across quarters, indicating predictable demand patterns. ## C. Europe & Emerging Markets * **Resilient International Growth:** International formulations emerged as a key growth pillar, delivering robust momentum across emerging markets and Europe on broad-based demand. * **Strategic Expansion:** Execution focus varies by region—therapy-led customization in emerging markets and portfolio expansion in Europe, with targeted entry into **Australia and India** and strengthened push in **France**. ## D. India Branded Business * **Outperformance Sustained:** India branded business continues to grow ahead of market, driven by innovation and pillar brands, with chronic therapies anchoring growth. * **Pipeline-Led Strategy:** A rich and diverse innovation pipeline supports long-term market outperformance and expansion into key therapeutic areas. ## E. Global Tenders * **Strategic Tender Wins:** Secured MR tender, positioning the company in major immunization programs, with active participation in TCV and upcoming typhoid tenders. * **Large-Scale Opportunity:** UNICEF typhoid tender represents a **80–100 Mn dose** annual opportunity, a potential catalyst upon contract award. --- # 4. R&D & Pipeline Progress ## A. Key Figures * **Saroglitazar PBC Trial:** Met **primary endpoint** with statistically significant biochemical response * **CUTX-101 Launch Timing:** On track for **potential launch between Jan–Jun 2026** * **Saroglitazar US Launch Timeline:** **6–12 months post-NDA**, depending on FDA review path ## B. Clinical Trial Results * **Pivotal Success in PBC:** Saroglitazar achieved primary and key secondary endpoints in Phase III, with data expected at **EASL or another major forum** within the year. * **Pipeline Momentum:** R&D intensity remains high despite trial completion, driven by new studies in **Usnoflast (Phase 2b)** and **Recurrent Pericarditis**. * **Expanded Therapeutic Potential:** Early signals show **benefits in pruritus and fatigue**, positioning Saroglitazar as a potential best-in-class therapy. ## C. Regulatory Submissions * **NDA on Track for USFDA:** Filing expected in **Q4 FY26**, with pre-launch focus on regulatory engagement and review readiness. * **Strategic Partnerships on Hold:** Management will await **data publication and NDA submission** before initiating formal discussions. ## D. Launch Pipeline * **Near-Term Launches Sequenced:** CUTX-101 to launch first, followed by Saroglitazar, with **commercial prep advancing in the US**. * **MedTech Growth Catalyst:** Imminent robotic system launch to drive **double-digit MedTech growth** in Europe and new markets. * **Robust Injectable Pipeline:** Resolution of facility issues enables **multiple product launches (vials, PFS, pens, dyes)** over next 2–3 years. * **Transdermal Expansion:** **One or two additional transdermal products** slated for filing, backed by dedicated manufacturing capacity. ## E. Innovation Projects * **Licensing Fuels Intangibles:** Development-stage intangible assets tied to **licensing**, including recently launched **Beizray**. --- # 5. M&A & Strategic Expansion ## A. Key Figures * **Acquisitions Completed:** **2 major deals** in the quarter: **Amplitude Surgical** (100% acquired) and **Comfort Click Limited** (first international acquisition) ## B. Acquisition Integration * **Strategic Portfolio Expansion:** Entry into high-growth **VMS** and **MedTech** segments via acquisitions, enhancing capabilities in **orthopedics, nephrology, cardiology**, and **digital consumer health**. * **Leadership & Retention Focus:** Founding teams of both **Comfort Click** and **Amplitude** committed to stay; **LTIPs** in place to ensure alignment and continuity. * **Margin Enhancement Potential:** **Cost reduction opportunities** identified in Amplitude’s sourcing and outsourcing, expected to offset pricing pressures and improve profitability. * **Commercial Strategy:** Zydus aims for **EBITDA-neutral or positive US product launches**; exploring **partnerships in developed markets** for **Saroglitazar** and **CUTX-101** to leverage existing access. ## C. Digital Health Entry * **Global Digital Platform Built:** Acquisition of **UK-based Comfort Click** establishes a **D2C e-commerce platform** with leading online market share in Europe, targeting **UK, EU, US, and future Middle East expansion**. * **High-Growth Consumer Model:** Comfort Click operates a **light-asset, self-owned digital platform** with **no incremental OpEx in Year 1**, strong brand loyalty, and **three scalable product lines** (human, pediatric, pet VMS). * **Market Tailwinds Leveraged:** Positioned to capitalize on rising **preventive healthcare trends** in the **£1,100 crore European VMS market**. * **MedTech Infrastructure Scaling:** **Nephro facility under construction**; dialyzer membrane production to serve **global markets**, with potential to be **among first Indian manufacturers** in this space. ## D. MedTech Growth Levers * **Innovation & Commercialization Focus:** Amplitude’s **CE-approved platform** and **near-launch robot** provide immediate growth levers; **TAVI trial underway in Europe** with India launch planned. * **Dialyzer Membrane Strategy:** Will **produce and sell final membrane product to partners**, targeting global consumable demand, not limited to domestic market. * **Growth Drivers Confirmed:** Amplitude delivers **double-digit growth** and **significant cost savings**, reinforcing ROI on acquisition. ## E. Future M&A Focus * **Capital Flexibility Secured:** **QIP approved** to fund strategic priorities including **US specialty expansion, international growth, and innovative asset acquisitions**. * **Targeted Therapeutic Focus:** M&A pipeline emphasizes **US and Europe specialty assets** in **pediatric rare diseases, gastroenterology, CNS (e.g., ALS), and cardiology**. * **No Immediate Deal, But Active Pipeline:** Evaluating opportunities in **US specialty, Europe, and Indian brand acquisitions**, with **MedTech as secondary** to core specialty focus. --- # 6. Risks & Regulatory Exposure ## A. Pricing Pressures * **Revlimid Genericization Looming:** Loss of exclusivity expected from Q4 onward, signaling near-term headwinds for related sales. * **Specialty Pricing Resilience:** Business in rare disease indications remains insulated from major pricing pressure due to **established pricing precedents** and limited competition. ## B. US Market Uncertainty * **Cautious Confidence in US Specialty:** Despite macro-level pricing and tariff uncertainties, management maintains a positive outlook, viewing the US specialty segment as a **viable investment zone** with acceptable risk. ## C. Device Regulations * **USFDA Inspections Conclude with Voluntary Actions:** Oncology injectable (Ahmedabad SEZ-1) and Baddi formulation facilities received EIRs indicating **voluntary agency actions**, not formal observations. * **European Pricing Cycles Priced In:** Medical device price negotiations every 3–4 years represent a moderate, **predictable risk**, with recent **3–4% reduction in France** aligned with normal regulatory patterns. --- # 7. Guidance & Outlook ## A. Key Figures * **Post-Acquisition Expense Run-Rate:** **₹1,500–1,550 Cr** * **Operating Margin Guidance:** **26%+** for full year * **Product Launches:** **25+** expected FY27 (10 in H1) ## B. Full-Year Targets * **Stable US Revenue Outlook:** Management expects to maintain current revenue levels in FY27 despite Revlimid loss, pending **February court decision** and supported by upcoming launches. * **Margin Resilience:** Operating margin guidance of 26%+ remains intact despite integration of lower-margin Comfort Click. * **Next Milestone:** Q3 results release scheduled for **February**, which will provide updated visibility. ## C. Launch Expectations * **Scaled Commercial Readiness:** Field force for Saroglitazar launch to be **60–80 personnel**, with hiring timed to regulatory clarity. * **Robust Launch Cadence:** Company on track for **25+ product launches** this year, reflecting strong pipeline execution and market expansion. ## D. Strategic Priorities * **Beyond-the-Pill Strategy:** Company advancing innovation across businesses to address broader patient needs and improve outcomes. * **Long-Term Focus:** Leadership reaffirms commitment to sustainable growth with disciplined, patient capital allocation.